News

,

Department seminar: Microfluidic Lab-on-a-Printer Platform Technology for Next Generation 3D Bioprinting December 4th 12-1pm

Professor Konrad Walus

University of British Columbia

Microfluidic Lab-on-a-Printer Platform Technology for Next Generation 3D Bioprinting

Date: Wednesday December 4th 12-1pm

Location: LAS 3033

Lunch bites will be provided.

Abstract:

3D bioprinting and related biofabrication and tissue engineering technologies are rapidly growing in significance and hold great potential for transformative impact in medicine, drug discovery, and basic R&D. 3D bioprinted tissues have been engineered to recapitulate both health and diseased states, enabling printed tissues to be used as a drug testing platform or as a basis of novel cell and tissue therapeutics.

The Walus group at UBC focuses on advancing 2D and 3D printing technologies for broad applications in printed electronics and biofabrication. In order to mimic the complex heterogeneity and optimized micro- nano-structure of tissue, our group helped to pioneer a novel bioprinting paradigm called Lab-on-a-Printer (LOP). The microfluidic enabled LOP concept involves integration of liquid manipulation directly with inkjet, filament or other deposition technology and allows for real-time programmability of bioink composition and the ability to multiplex multiple material inputs into one output dispenser. In this talk, Prof. Walus will describe progress in microfluidic enabled 2D/3D printing with a focus on biofabrication and related applications. Development of this technology has resulted in an award-winning Canadian biotechnology spin off company from UBC, called Aspect Biosystem Ltd. In addition to a technical description of the technology, Walus will briefly describe the path from an idea in the lab to an internationally recognized 3D bioprinting company.

Speaker:

Dr. Konrad Walus received a B.A.Sc. in Electrical Engineering from the University of Windsor in 2001, and a Ph.D. degree in Electrical Engineering from the University of Calgary, Calgary, Canada, in 2005. He has been at The University of British Columbia since 2005 and is presently a Professor in the Department of Electrical and Computer Engineering.

Dr. Walus has an extensive record of interdisciplinary contributions to the field of functional printing technology and 3D bioprinting, nearly 100 refereed publications in the broader area of microsystems and nanotechnology. With his research team, he pioneered the emerging area of microfluidic 3D bioprinting, a technology capable of multi-material 3D biofabrication using crosslinkable hydrogels as a tissue engineering scaffold. In 2013, Dr. Walus co-founded one of Canada’s most promising biotechnology companies, Aspect Biosystems Ltd (2019 BCs Growth Stage Company of the Year, 2018 BIOTECanada Emerging Company of the Year, and 2016 BC’s Most Promising Company). In 2017, he was invited to speak in a televised session at the Senate of Canada: Standing Senate Committee on Social Affairs, Science and Technology on the importance of 3D printing in healthcare. He has served on the Board of Directors for the Medical Device Development Centre in Vancouver, a non-profit focusing on supporting medical innovation and entrepreneurship in BC. He was awarded the Alberta Science and Technology Foundation Leaders of Tomorrow award for his innovative Ph.D. work on computational nanotechnology. Konrad is a co-founder of the Microsystems and Nanotechnology (MiNa) group at UBC and developed and coordinated the UBC Nanotechnology and Microsystems Undergraduate Option in Applied Science. He has also served as the Director of the Electrical Engineering Undergraduate Program at UBC.

Related News